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Summary.-This paper discusses the results of experiments using y-rays and a
hypoxic sensitizer metronidazole (MET) and also awell-known protector, mercapto-
ethylamine (MEA), individually and in combination, on the survival of the yeast S.
cerevisiae BZ 34. MET (5mM) gave a hypoxic enhancement ratio (ER) of 13. MEA
(5mM, 10mM) gave a dose-modifying factor (DMF) of 19 and 2-3 respectively for
euoxic cells. However, the DMFs for hypoxic cells were 1.0 and 1-1 for 5 and 10mM
concentrations ofMEA. Acombination of5mM MEAand5mM MET gave a DMF of 2-0
for euoxic cells and the ER remained at 1-3 for hypoxic cells. The "effective" oxygen
enhancement ratios were 2-3 and 1-7 for the control and the sensitizer respectively.
In the combination this value was equal to or even slightly less than 1. All DMF,
ER and OER values were derived from Do values of the survival curves. The values
based on 10% survival are almost equal to those derived from Do values. All the sur-
vival curves gave the same extrapolation number, showing that the chemicals in-
dividually or in combination were truly dose-modifying.
These results indicate that protectors such as MEA could be preferentially protect-
ing euoxic cells, and that combining such "oxic protectors" with a hypoxic sensitizer
could result in protecting euoxic cells while the sensitization of hypoxic cells was not
much reduced. The implications of our results for radiotherapy are discussed. It
appears that the use of nontoxic oxic protectors may be a useful adjuvant in over-
coming the hypoxic-cell problem in radiotherapy.
THE PRESENCE of hypoxic cells in
tumours may contribute to the failure of
radiation therapy because of their greater
resistance to radiation than that of the
euoxic cells. Possibilities for dealing with
this problem are the use of (1) hyperbaric
oxygen; (2) fractionated therapy sched-
ules; (3) high-LETradiation, or (4) hypoxic
sensitizers. The recent interest generated in
sensitizers which preferentially sensitize
hypoxic cells has led to consideration of
their use in radiotherapy (Adams and
Cooke, 1969; Denekamp, Michael and
Harris, 1974; Moore, Palcic and Skarsgard,
1976; Foster and Willson, 1973; Asquith et
al., 1974; Chapman et al., 1972). Recent
clinical trials show encouraging results
which may be of help in radiation therapy
(Urtasun et al., 1975, 1977; Deutsch et al.,
1975; Thomlinson et al., 1976).
Radioprotectors would have been of use
in radiotherapy, if their high toxicity had
notdiscouraged their use (Maisin, Lambiet-
Collier and Mattelin, 1976). Recently
Utley et al. (1974) have shown that the
compound WR-2721 had differential pro-
tection for hypoxic and euoxic cells in
vivo, and suggested that it could be used in
radiotherapy. Similar observations with
the same compound were made by Yuhas
(1973). To reduce the toxic effect of the
protectors, a combination of protectors
was recently proposed (Maisin et al.,
1976; Sztanyik and Santha, 1976). Similar
studies on the combination of hypoxic
sensitizers of different modes of action are
also being actively pursued (Millar, Fielden
and Smithen, 1977). We have shown
hypoxic sensitization by MET on survival
ofyeast and favourable split-dose recoveryHYPOXIC CELL SENSITIZER PLUS OXIC PROTECTOR
properties (Krishnan et al., 1977, Krishnan
et al., unpublished). Many radioprotective
substances are known to protect well
oxygenated cells to a greater extent than
relatively hypoxic cells (Alper, 1962;
Bridges, 1962; Antoku, 1975, 1977).
We have used the sulphydryl compound
MEA in experiments with yeast. We
found MEA to be a clear differential
protector of euoxic cells. In this paper we
report our findings for the combination of
an oxic protector MEA and a hypoxic
sensitizer MET on yeast. The implications
of these results for radiotherapy are
discussed.
MATERIALS AND METHODS
Culture andgrowth media.-The yeast strain
S. cerevisiae BZ 34 used and the details
of maintenance, growth media, genotype etc.
are given elsewhere (Singh, Mahajan and
Krishnan, 1976).
Chemicals.-All chemicals were freshly pre-
pared in distilled water and sterilized by
filtering through a 0-45,um millipore filter
paper. MEA (cysteamine) was obtained from
BDH, England; MET ('Flagyl') was a gift
sample from May and Baker, India. No
further purification of chemicals was done.
MET solutions were kept covered against
exposure to light. Experiments with MET
were done for 0-1, 1 and 10mM final concentra-
tions, and the results were identical, as given
elsewhere (Krishnan et al., 1977). MEA solu-
tions were adjusted to pH 6-5-7-0 with dilute
NaOH just before use. Final concentrations
used for experiments were 5 and 10mM. The
combination of MEA and MET consisted of
5mM each.
Toxicity studies ofchemicals.-Before radia-
tion experiments were done the chemicals
were tested individually and in combination
for toxicity to yeast, suspended in sterile
distilled water both under euoxic and hypoxic
conditions. Thetoxicitieswereusuallychecked
at the highest concentrations and over the
longest contact times, used in the experi-
ments. For toxicity studies, 106 cells/ml in
euoxic conditions or 108 cells/ml in hypoxic
conditions were kept in the chemical solution
for the required length of time at room
temperature. Then the chemical was washed
offand the cells plated. MEA was found to be
non-toxic to yeast up to 8 h at 50mM. MET
causednegligible cellkillingupto4h at 10mM.
At higher concentrations, MET caused ap-
preciable cell killing, both in euoxic and in
hypoxic conditions. A combination of 5mM
each ofMEAandMET gave 100% survivalup
to 6h.
Sample preparations.-Yeast cells used
were always suspended in sterile distilled
water with or without the chemical(s), at
least 30 min before irradiation. For euoxic
irradiation 2ml of the sample of 106 cells/ml
was taken in a test tube of 15ml capacity and
loosely stoppered to allow air exchange.
Production of hypoxic condition.-For ir-
radiation under hypoxic conditions, the auto-
anoxia method of Pohlit (1973), as detailed
elsewhere (Krishnan et al. 1977), was used.
Pyrex volumetric-standard vial (1 or 2ml
capacity) with ground-glass tight fitting
stopper was filled fully without air bubbles,
with a cell suspension of 108 cells/ml and
tightly stoppered. These samples were in-
cubated for 30 min at 30°C. An oxygen con-
sumption rate of 2-2 x 10-16 mol/cell/min
by the concentrated cell suspension (10 cells/
ml) ensures hypoxic condition within 20 min
(Pohlit, 1973).
Irradiation and dosimetry.-All irradiations
were done in a gamma cell (Isotope Division,
BARC) at a dose rate of 5-5 krad/min and a
transit dose of500 rad per operation. The dose
at various positions inside the irradiation
chamber was measured using the Fricke dosi-
meter. It was observed that there was
appreciable (5%) difference in the dose rates
at the centre and at the periphery of the
chamber. Therefore all the samples for irradi-
ation were kept along the annulus at the
periphery of the irradiation chamber in a
beaker 8 cm in diameter with packing in the
centre. The same irradiation geometry was
maintained for all the experiments. All the
samples were irradiated within a total period
of I h.
Treatment of samples.-One ml of cell
suspension from the irradiated sample was
filtered through a 0 45 ,um filter paper in a
Millipore filter assembly. The filter paper was
resuspended in 10 ml water and shaken in a
Vortex shaker to get the cells in water.
Appropriate dilutions were plated in 4
YEPD plates to get -250 colonies/plate, to
avoid any errors arising from small numbers
of colonies. Plating was done as soon as
possible after irradiation, and the cells were
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kept at low temperature (4°C) between
irradiation and filtering. Themilliporefiltering
method of washing off the chemical was used
whether the samples contained the chemical




The diploid yeast S. cerevisiae BZ 34
used for all these studies has a shouldered
survival curve. The Do values in euoxic and
hypoxic conditions are 22 and 50 krad
respectively. The oxygen enhancement
ratio (OER) is 2-3. The parameters such as
OER, enhancement ratio (ER) of a hy-
poxic sensitizer and dose-modifying factor
(DMF) of a protector were estimated from
the Do values. These values do not how-
ever differ much from the values based on
10%0 survival levels. All the survival
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FIG. 1. Effect of 5mM metronidazole (MET)
on the y-ray survival ofyeast. Pooled results
of at least 2 experiments, the bars showing
maximum spread in values. 0 control,
euoxic; 0 MET duiring irradiation, euoxic;
A control, hypoxic; A with MET (luring
irradiation, hypoxic.
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FIG:. 2. Effect of 5 and 10mM mercapto-
ethylamine (MEA) on the y-ray survival of
yeast. The control lines (viz. euoxic and
hypoxic without added chemical) are re-
produced from Fig. 1. The points with
added MEA during irradiation, are pooled
results of two experiments. The maximum
spread in survival of each point plotted are




3 (0 5mm MEA, euoxic;
4 0 5mM MEA, hypoxic;
5 Z 10mM MEA, euoxic;
6 * 10mM MEA, hypoxic.
ber (n 2) showing that the effects of
the chemicals and of oxygen were all truly
dose-modifying. Pooled results of a large
number of experiments were used to give
the survival curves, viz. survival under
euoxic and hypoxic conditions in the
absence of added chemical. For survival
experiments with chemicals, results of at
least two experiments under identical
conditions were pooled and plotted. The
bars in Fig. 1 represent the maximum
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spread of observed experimental values.
These were not represented in Figs. 2 & 3,
toincrease clarityasbetweentheindividual
survival curves. The individual survival
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FIGc. 3. Effect of mixture of 5mm MET and
5mM MEA on the y-ray survival of yeast.
The survival curves for the controls and for
5mM MET are reproduced from Fig. 1 for
comparison. The experimental con(iitions
and spreads are as in Fig. 2
1 control, euoxic;
2 control, hypoxic;
3 MET 5mM, euoxic;
4 MET 5 mM, hypoxic;
5 0 mixture, euoxic;
6 M Mixture, hypoxic.
calculated from regression analysis were
not significantly different from those
obtained from these survival curves. The
standard errors in Do values were calcu-
lated using all the observed survival
points for each dose.
Hypoxic 8en8itization of metronidazole
Metronidazole (Flagyl, MET) is known
to be a hypoxic sensitizer in vivo and in
vitro (Foster and Willson, 1973; Denekamp
et at., 1974). We have also found (Krishnan
et al., 1977) an enhancement ratio of 1-3 at
ImM MET on our yeast system. However,
0.1, I and 10mM MET gave similar survival
curves. For the sake of later comparison
this graph is reproduced as Fig. 1.
Differential protection of MEA
We have used MEA, a well known
chemical protector, onyeastandobtained a
euoxic protection for concentrations of 5
and 10 mM, and negligible protection of
hypoxic cells. These results are given in
Fig. 2. They represent DMFs of 1-9 and 2-3
for 5mM and 10mM MEA respectively on
euoxic cells, and 1-0 and 1 1 on hypoxic
cells. It can be seen that whilst the euoxic
DMF is almost equal to that of OER, there
is no appreciable protection for hypoxic
cells. Thus, MEA clearly shows a differen-
tial protection of euoxic cells. Such a
property of this chemical can also be seen
in recent literature (Antoku, 1975, 1977).
Effect of a combination of MEA and MET
As shown above, METsensitizes hypoxic
cells with an ER of 1-3 and MEA preferen-
tially protects euoxic cells with a DMF of
2*3. A combination of hypoxic sensitizer
with a chemical protector preferentially
protecting euoxic cells will protect euoxic
(normal) cells while the hypoxic cells re-
main sensitized, provided the combina-
tion is free of interaction. To test this
hypothesis we have used a combination of
MET and MEA at equimolar (5mM)
concentrations. y-Ray survival curves
using this combination are given in Fig. 3.
The combination gave a survival curve for
hypoxic cells identical to that of the
hypoxic sensitizer (Lines 4 and 6 in Fig. 3).
The combination gave a survival curve for
euoxic cells with a DMF of 1 7 (Line 5 in
Fig. 3). The slope of the survival curve of
hypoxic cells with the combination of
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MEA + MET (5mMN each)
MEA 10mmr
Do (krad) + s.e.
Euoxic Hypoxic
22± 0-5 50 ± 2-7
22 0-9 38 ± 0-8
42 1 9. 50 i 1-8
44 - 1- :38 ± 1-4
50 4- 2 3 54 ± 1 2
Ratio of Do's
i.e. OER ± s.e.
(or effective OER)





chemicals is actually even slightly less than
that ofeuoxic cells with the same combina-
tion (0 86±0-05). It appears that the
"hypoxic cell problem" could be over-
come by using such a combination of
chemicals.
Table I gives the Do and OER values of
the survival lines of Fig. 1, 2 and 3. The
OER values are calculated from the Do
values. The standard error in OER is given
by the well known formula (Topping,
1965)
A[X] -[(X) 2 + (Ay) 2] 1/2
where X -Do of hypoxic cells, and Y -
Do of euoxic cells, and AX and AY are the
standard errors in X and Y respectively.
DISCUSSION
Possible use ofprotectors in radiotherapy
As early as 1967, Alper stated that "'it
has been observed (Cohen and Cohen,
1959) both with microorganisms and with
mammalian cells that protection by chemi-
cal agents is less effective when no oxygen
is present during irradiation". She also
suggested that an agent could be found
which would protect the aerobic normal
cells more effectively than the anoxic
tumour cells. Yuhas and Storer (1969)
have also found that the thiophosphate
compound WR-2721 protected irradiated
healthy tissues in a tumour-bearing mouse,
but did not protect the tumour itself.
Harris and Phillips (1971), Utley et al.,
(1974) and Phillips (1977) have reported
similar results. All these reports indicate
that some radioprotective chemicals can
show a differential protection of euoxic
cells rather than hypoxic cells. From Fig. 2
it can be seen that the differential protec-
tion of MEA is considerable in our in vitro
studies.
The OER value, as seen in Table I,
reduces when MET is present because ofits
property ofspecifically sensitizing hypoxic
cells. Similarly the differential production
of MEA for euoxic cells reduces OER.
Extension of our results to radiotherapy
Results of in vitro split-dose experi-
ments with RO-07-0582 (Hall and Roizin-
Towle, 1975) and MET (Krishnan et al.,
unpublished) have shown that these
chemicals have favourable in vitro radio-
biological properties for use in fractionated
radiotherapy. Similar studies on protectors
and also combinations of sensitizer and
protector may be fruitful.
Our results with MEA having a DMF
in euoxic conditions as high as OER itself
may be an extreme case ofoxic protection.
Thus, use of our results may not reflect
typical values obtainable. Therefore, for
the purposes ofdemonstrating the possible
use of these results in radiotherapy, we
have assumed some typical values for the
parameters. For the same reason, an OER
of 2X5 is assumed for y-rays, even though
our experimental values were 2-2 2-3.
Table II gives the OER values expected on
the basis of these assumed parameters. It
can be seen that the expected OER values
for a combination of chemicals with y-rays
is midway between those of fast neutrons
and high LET radiation. Thus it appears
that using a mixture of hypoxic sensitizer
and oxic protector might make y radiation
itself as useful as other radiations for
radiotherapy in so far as the "hypoxic cell
problem" is concerned. However, one is
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TABLE II. Expected OER Valuesfor Different Conditions.
Condition OER Assumed parameters
1. y Alone 2-5
2. y + Hypoxic sensitizer 1 9 ER = 1 3
3. y + oxic protector 1 -7 DMF (02)/DMF (N2) = 1 -5
4. y + combination of
protector and sensitizer 1 *25 ER, DMF ratio as above
5. Fast neutrons 1-7
6. High-LET radiation 1*0
ER = Hypoxic enhancement ratio of a hypoxic sensitizer;
DMF = Dose-modifying factor of a protector.
aware also that conclusions extrapolated
from experiments in vitro may not hold
exactly in vivo, and that tumours do not
consist entirely ofhypoxic cells. The other
factors associated with therapy, such as
cell-stage sensitivity etc., may still pose a
problem in cancer cure.
While revising our manuscript we came
across arecent paperbyYuhas etal. (1977).
These workers have used a combination of
WR-2721, a radioprotective chemical, and
RO-07-0582, a hypoxic radiosensitizer, on
transplanted tumours in mice. Their
results are in line with our in vitro studies.
We wish to thank Dr K. G. Vohra, Head, Division
of Radiological Protection for his interest, and Smt.
Vaishali V. Deorukhakar, Shri M. S. Sidhartan and
Shri E. S. Sawal for their assistance.
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